AZN חוב כולל להון AstraZeneca AB

AstraZeneca PLC (AZN) relies on a diversified drug portfolio, reducing its dependence on local regulators. However, geopolitical tensions complicate international logistics and the conduct of clinical trials. Dominance in oncology and innovative developments protect margins from generics. The total debt-to-equity ratio helps assess leverage risks, where 0.59 reflects the baseline level of the metric.

Scaling the oncology portfolio of AstraZeneca PLC (AZN) allows the company to expand margins by leveraging its existing global distribution. The total liabilities-to-equity ratio measures the proportion of borrowed funds within the asset financing structure. This coefficient determines the business's level of dependence on creditors and the associated debt service risks. Excessive growth of this indicator signals that cash flow is becoming overburdened. By analyzing the company's financial leverage chart, an investor assesses the balance between debt load and growth potential.